Total Payments
$150,748
2024 Payments
$567.86
Companies
80
Transactions
610
Medicare Patients
3,361
Medicare Billing
$324,297
Payment Breakdown by Category
Other$65,297 (43.3%)
Research$62,131 (41.2%)
Food & Beverage$11,745 (7.8%)
Consulting$7,525 (5.0%)
Travel$4,032 (2.7%)
Education$17.66 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,297 | 38 | 43.3% |
| Unspecified | $62,131 | 1 | 41.2% |
| Food and Beverage | $11,745 | 548 | 7.8% |
| Consulting Fee | $7,525 | 6 | 5.0% |
| Travel and Lodging | $4,032 | 16 | 2.7% |
| Education | $17.66 | 1 | 0.0% |
Payments by Type
General
$88,617
609 transactions
Research
$62,131
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $66,359 | 101 | $0 (2024) |
| Eli Lilly and Company | $62,131 | 1 | $0 (2018) |
| EISAI INC. | $7,272 | 16 | $0 (2022) |
| Stemline Therapeutics Inc. | $3,360 | 2 | $0 (2021) |
| Incyte Corporation | $2,522 | 21 | $0 (2023) |
| Lilly USA, LLC | $1,033 | 53 | $0 (2021) |
| Merck Sharp & Dohme LLC | $825.09 | 18 | $0 (2024) |
| Exelixis Inc. | $537.26 | 18 | $0 (2023) |
| Covidien LP | $515.25 | 4 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $502.66 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $567.86 | 20 | AstraZeneca Pharmaceuticals LP ($112.37) |
| 2023 | $384.21 | 20 | Mirati Therapeutics, Inc. ($54.12) |
| 2022 | $8,209 | 50 | EISAI INC. ($4,397) |
| 2021 | $30,050 | 153 | AstraZeneca Pharmaceuticals LP ($22,597) |
| 2020 | $2,377 | 120 | Eisai Inc. ($573.25) |
| 2019 | $21,402 | 61 | AstraZeneca Pharmaceuticals LP ($20,129) |
| 2018 | $74,378 | 91 | Eli Lilly and Company ($62,131) |
| 2017 | $13,379 | 95 | AstraZeneca Pharmaceuticals LP ($11,903) |
All Payment Transactions
610 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $34.24 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.53 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $46.85 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $16.12 | General |
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.12 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $27.84 | General |
| Category: Oncology | ||||||
| 08/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.91 | General |
| Category: Oncology | ||||||
| 07/26/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $31.52 | General |
| Category: DESMOID TUMORS | ||||||
| 07/10/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Oncology | ||||||
| 04/17/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $112.37 | General |
| Category: Oncology | ||||||
| 03/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $33.51 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: HORMONE THERAPY | ||||||
| 02/19/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Oncology | ||||||
| 02/15/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $21.88 | General |
| Category: Oncology | ||||||
| 02/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.30 | General |
| Category: Oncology | ||||||
| 02/05/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $32.08 | General |
| Category: ONCOLOGY | ||||||
| 01/13/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: Oncology | ||||||
| 12/20/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TECVAYLI | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Oncology | ||||||
| 12/07/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $26.01 | General |
| Category: Hematology/Oncology | ||||||
| 12/05/2023 | PFIZER INC. | IBRANCE (Drug), COMIRNATY | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1A-1B TRIAL INVESTIGATING THE CSF-1R INHIBITOR LY3022855 IN COMBINATION WITH DURVALUMAB -MEDI4736- OR TREMELIMUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Eli Lilly and Company | $62,131 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 507 | 2,005 | $216,324 | $59,586 |
| 2022 | 24 | 731 | 2,376 | $219,199 | $60,522 |
| 2021 | 26 | 953 | 3,796 | $274,537 | $82,010 |
| 2020 | 28 | 1,170 | 6,141 | $412,265 | $122,179 |
Total Patients
3,361
Total Services
14,318
Medicare Billing
$324,297
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 276 | $93,564 | $25,974 | 27.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 44 | 150 | $56,700 | $14,304 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 46 | $21,804 | $6,037 | 27.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 94 | 485 | $4,365 | $4,074 | 93.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 93 | 380 | $11,020 | $2,839 | 25.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 15 | 49 | $8,722 | $2,148 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 26 | $6,214 | $1,618 | 26.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 45 | $3,555 | $883.55 | 24.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 11 | 32 | $2,688 | $569.73 | 21.2% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 19 | 56 | $2,352 | $508.04 | 21.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 27 | $1,863 | $272.50 | 14.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 11 | 35 | $2,135 | $259.23 | 12.1% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 20 | 37 | $259.00 | $70.92 | 27.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 18 | 361 | $1,083 | $28.54 | 2.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 263 | $89,157 | $25,625 | 28.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 37 | 134 | $50,652 | $13,862 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 48 | 48 | $22,752 | $6,415 | 28.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 89 | 366 | $10,614 | $2,767 | 26.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 13 | 35 | $6,230 | $1,801 | 28.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 48 | 135 | $5,265 | $1,398 | 26.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 103 | 453 | $4,077 | $1,332 | 32.7% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2022 | 19 | 49 | $3,430 | $906.88 | 26.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 12 | 17 | $3,213 | $845.24 | 26.3% |
| 86301 | Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | Office | 2022 | 13 | 40 | $3,000 | $827.99 | 27.6% |
| 83735 | Magnesium level | Office | 2022 | 37 | 109 | $2,725 | $726.14 | 26.6% |
About Dr. Judy Wang, MD
Dr. Judy Wang, MD is a Medical Oncology healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2009. The National Provider Identifier (NPI) number assigned to this provider is 1053554717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Judy Wang, MD has received a total of $150,748 in payments from pharmaceutical and medical device companies, with $567.86 received in 2024. These payments were reported across 610 transactions from 80 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($65,297).
As a Medicare-enrolled provider, Wang has provided services to 3,361 Medicare beneficiaries, totaling 14,318 services with total Medicare billing of $324,297. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Sarasota, FL
- Active Since 04/10/2009
- Last Updated 09/02/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1053554717
Products in Payments
- TAGRISSO (Drug) $29,672
- IMFINZI (Drug) $24,631
- IMFINZI (Biological) $11,382
- Lenvima (Drug) $7,261
- ELZONRIS (Drug) $3,360
- MK-8353 (Drug) $656.25
- CYRAMZA (Drug) $608.35
- Cabometyx (Drug) $506.15
- OPDIVO (Biological) $470.05
- IMBRUVICA (Drug) $390.75
- GastriSail (Device) $345.10
- CALQUENCE (Drug) $213.62
- TASIGNA (Drug) $192.44
- VERZENIO (Drug) $168.98
- TUKYSA (Drug) $168.07
- LYNPARZA (Drug) $167.20
- BRAFTOVI (Drug) $159.40
- KEYTRUDA (Biological) $150.40
- ADCETRIS (Biological) $149.38
- MONJUVI (Drug) $148.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Sarasota
Anjan Patel, M.d, M.D
Medical Oncology — Payments: $10,287
Medical Oncology $10,287
Dr. Jayan Nair, M.d, M.D
Medical Oncology — Payments: $6,609
Medical Oncology $6,609
Dr. Steven Denstman, M.d., Phd, M.D., PHD
Medical Oncology
Medical Oncology
Jameel Audeh
Medical Oncology
Medical Oncology
Dr. Maria Mallarino, M.d, M.D
Medical Oncology
Medical Oncology